Comparison of concurrent alterations of other genes between patients with AML with and without ASXL1 mutations
| . | Total patients (N = 501), % (n/N) . | Patients with ASXL1-mutated (N = 54), % (n/N) . | Patients with ASXL1-wild-type (N = 447), % (n/N) . | P . |
|---|---|---|---|---|
| FLT3-ITD | 23.1 (116/501) | 7.4 (4/54) | 25.0 (112/447) | .003 |
| NPM1 | 21.0 (105/501) | 3.7 (2/54) | 23.0 (103/447) | < .001 |
| CEBPA | 13.0 (65/501) | 7.4 (4/54)) | 13.6 (61/447) | .282 |
| RUNX1 | 12.2 (61/501) | 29.6 (16/54) | 10.1 (45/447) | < .001 |
| NRAS | 11.6 (58/501) | 11.1 (6/54) | 11.6 (52/447) | .909 |
| FLT3-TKD | 8.2 (41/501) | 9.3 (5/54) | 8.1 (36/447) | .791 |
| WT1 | 6.6 (33/501) | 0 (0/54) | 7.4 (33/447) | .038 |
| MLL-PTD | 5.4 (27/501) | 5.6 (3/54) | 5.4 (24/447) | > .999 |
| IDH1 | 5.4 (27/501) | 1.9 (1/54) | 5.8 (26/446) | .342 |
| PTPN11 | 4.2 (21/501) | 9.3 (5/54) | 3.6 (16/447) | .064 |
| KRAS | 3.4 (17/501) | 0 (0/54) | 3.8 (17/447) | .238 |
| KIT | 2.8 (14/501) | 3.7 (2/54) | 2.7 (12/447) | .655 |
| JAK2 | 0.8 (4/501) | 0 (0/54) | 0.9 (4/447) | > .999 |
| . | Total patients (N = 501), % (n/N) . | Patients with ASXL1-mutated (N = 54), % (n/N) . | Patients with ASXL1-wild-type (N = 447), % (n/N) . | P . |
|---|---|---|---|---|
| FLT3-ITD | 23.1 (116/501) | 7.4 (4/54) | 25.0 (112/447) | .003 |
| NPM1 | 21.0 (105/501) | 3.7 (2/54) | 23.0 (103/447) | < .001 |
| CEBPA | 13.0 (65/501) | 7.4 (4/54)) | 13.6 (61/447) | .282 |
| RUNX1 | 12.2 (61/501) | 29.6 (16/54) | 10.1 (45/447) | < .001 |
| NRAS | 11.6 (58/501) | 11.1 (6/54) | 11.6 (52/447) | .909 |
| FLT3-TKD | 8.2 (41/501) | 9.3 (5/54) | 8.1 (36/447) | .791 |
| WT1 | 6.6 (33/501) | 0 (0/54) | 7.4 (33/447) | .038 |
| MLL-PTD | 5.4 (27/501) | 5.6 (3/54) | 5.4 (24/447) | > .999 |
| IDH1 | 5.4 (27/501) | 1.9 (1/54) | 5.8 (26/446) | .342 |
| PTPN11 | 4.2 (21/501) | 9.3 (5/54) | 3.6 (16/447) | .064 |
| KRAS | 3.4 (17/501) | 0 (0/54) | 3.8 (17/447) | .238 |
| KIT | 2.8 (14/501) | 3.7 (2/54) | 2.7 (12/447) | .655 |
| JAK2 | 0.8 (4/501) | 0 (0/54) | 0.9 (4/447) | > .999 |
AML indicates acute myeloid leukemia; ITD, internal tandem duplication; TKD, tyrosine kinase domain; and PTD, partial tandem duplication.